Skip to main content
. Author manuscript; available in PMC: 2022 Jan 20.
Published in final edited form as: Ann Hematol. 2020 Jun 1;100(1):143–155. doi: 10.1007/s00277-020-04094-3

Fig. 4.

Fig. 4

Stroke prevention in patients with treatment-emergent AF

Anticoagulation agents: apixaban n=15 (29%), rivaroxaban n=5 (10%), enoxaparin n=3 (6%), dabigatran n=1 (2%), warfarin n=1 (2%)

Antiplatelet agents: aspirin 81 mg n=9 (18%), aspirin 325 mg n=2 (4%), dual antiplatelet therapy n=1 (2%)